
Kronos Bio, Inc. (NASDAQ: KRON), relating to the proposed merger with Concentra Biosciences, LLC. Under the terms of the agreement, Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock, plus one non-tradeable contingent value right.